In vivo inhibitory effect of suberoylanilide hydroxamic acid combined with sorafenib on human hepatocellular carcinoma cells. Brazilian Journal of Pharmaceutical Sciences, [S. l.], v. 56, p. e18254, 2020. DOI: 10.1590/s2175-97902019000318254. Disponível em: https://www.revistas.usp.br/bjps/article/view/181441.. Acesso em: 16 may. 2024.